Treatment News : Follow-Up Study Confirms Pneumonia Might Be More Common in Fuzeon Users

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 29, 2011

Follow-Up Study Confirms Pneumonia Might Be More Common in Fuzeon Users

The U.S. Food and Drug Administration (FDA) has announced that people taking the antiretroviral drug Fuzeon (enfuvirtide) might indeed be at a higher risk of developing serious bacterial pneumonia while taking the drug.

During the review of the two Phase III studies that led to the approval of Fuzeon, researchers found that the risk for developing bacterial pneumonia was nearly twelve-fold higher in those taking Fuzeon than in those who received a placebo. Approximately half of those who developed pneumonia while taking Fuzeon had to be hospitalized, and three people died.

People in the Phase III studies had very advanced HIV disease, however, and a number of other AIDS-related complications. This made it difficult to be certain whether the additional pneumonia cases were due to Fuzeon or if they were simply a fluke.

To test this, the FDA required Fuzeon’s maker (then Roche and now Genentech) to conduct a large post-approval clinical trial involving 1,850 people—740 taking Fuzeon and 1,110 not taking the drug.

The recently completed study once again suggested an association between the use of Fuzeon and a higher risk for pneumonia, though to a lesser degree than in the original Phase III studies. The additional risk, after adjusting for other factors, was 34 percent.

For this reason, the new prescribing information for Fuzeon will now state: “It is unclear if the increased incidence of pneumonia is related to FUZEON use. However, because of these findings, patients with HIV-1 infection should be carefully monitored for signs and symptoms of pneumonia, especially if they have underlying conditions which may predispose them to pneumonia.”

Search: Fuzeon, enfuvirtide, bacterial pneumonia, FDA


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    RyGuy00
    New York
    New York


    sefarady
    New York
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.